This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Respiratory Syncytial Virus (RSV)
  • /
  • Immunogenicity, Safety, Reactogenicity and Persist...
Clinical trial

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Read time: 1 mins
Last updated:19th Oct 2021
Status: Active, not recruiting
Identifier: NCT04732871
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above


The purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 3 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in adults aged 60 years and above. The study will also evaluate the immunogenicity, safety and reactogenicity of additional vaccine doses given according to different revaccination schedules.


Study Type: Interventional (Clinical Trial)
Actual Enrollment: 1720 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description: Open-label study. Both investigator and participant know the identity of the intervention assigned.
Primary Purpose: Prevention
Official Title: A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
Actual Study Start Date: February 15, 2021
Estimated Primary Completion Date: May 24, 2022
Estimated Study Completion Date: May 24, 2024

Arm:
- Experimental: Group A
- Experimental: Group B
- Experimental: Group C

Category Value
Study type(s) Interventional
Actual enrolment 1720
Actual Study start date 15 February 2021
Estimated Study Completion Date 24 May 2024

View full details